Last edition
News about
Gilead Expands Oncology Pipeline with Tubulis Acquisition
Gilead to acquire Tubulis, adding TUB-040 ADC for ovarian cancer and a next-generation platform with Tubutecan technology, strengthening its oncology pipeline and ADC capabilities.
IDF President-Elect meets Dr. Jitendra Singh to boost indigenous biosimilar insulin production and diabetes biomanufacturing in India, focusing on affordability, supply security, and industry collaboration.
Bayer Updates Access Model for Eylea 2mg in India
Bayer revises its access model for Eylea 2mg in India to expand patient eligibility and reduce upfront costs, enabling earlier treatment for retinal diseases.
Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US
Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.
CuraTeQ Biologics Announces Positive Phase 3 Results for BP11, Biosimilar to Xolair
CuraTeQ Biologics reports positive Phase 3 results for BP11, a biosimilar to Xolair, meeting primary endpoints in Chronic Spontaneous Urticaria (CSU) studies across Europe and India.
Alembic Pharmaceuticals Gains USFDA Approval for Dapagliflozin Tablets ANDA
Alembic Pharmaceuticals receives USFDA approval for Dapagliflozin Tablets ANDA, gaining eligibility for 180-day shared generic drug exclusivity and strengthening its diabetes portfolio.
Alpha Cognition Secures US Patent for ALPHA-1062 in Traumatic Brain Injury Treatment
New patent protection through 2045 strengthens pipeline expansion beyond Alzheimer’s disease and targets unmet need in TBI therapeutics.
.
Transgene, NEC Bio B.V. Sign Licensing Deal to Advance AI-Driven Cancer Vaccine
Transgene's Agreement wirh NEC Bio B.V. to accelerate development of TG4050, a personalised neoantigen immunotherapy for head and neck cancer, combining viral vector technology with AI-based prediction.
Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal
The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.
Trialt Partners with Viedoc to Streamline Clinical Trials and Enhance Data-Driven Decision-Making
The strategic collaboration between Trialt Partners and Viedoc integrates biometrics expertise with cloud-based eClinical technology to accelerate timelines and improve data quality across global studies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy